Jason Litten, M.D.
Chief Medical Officer
Jason B. Litten, M.D., has more than 11 years of biotech industry experience. He was most recently CMO at Optera Therapeutics. Prior to Optera, Jason was VP of Clinical Development at Juno Therapeutics, a cell therapy company, where he oversaw clinical development for all of Juno’s solid tumor CAR and TCR programs. Prior to Juno he was Vice President of Clinical Development at Clovis Oncology, where he led the lucitanib and rociletinib clinical programs. Jason started his industry career in Clinical Development at Amgen supporting development of trebananib and panitumumab (Vectibix©). Jason holds a B.S. from Cornell University and M.D. from Emory University. He was a Resident Physician in General Pediatrics at University of Miami and Clinical Fellow in Pediatric Hematology & Oncology at UT Southwestern.